Key result
Low-dose NOACs show comparable LAAT resolution to standard-dose at three months without major bleeding.
Why the study?
Data comparing different doses of NOACs for resolution of left atrial appendage thrombus in nonvalvular AF were scarce.
Do low-dose NOACs resolve left atrial appendage thrombus as effectively as standard-dose NOACs in patients with nonvalvular atrial fibrillation?
Cohort (n=24)
No
Do low-dose NOACs resolve left atrial appendage thrombus as effectively as standard-dose NOACs in patients with nonvalvular atrial fibrillation?
Low-dose NOACs appear to be a safe and effective alternative to standard-dose NOACs for resolving left atrial appendage thrombus in specific subsets of patients with nonvalvular AF.
Answers are grounded in this paper and cite their sources.
Low-dose NOACs were associated with comparable LAAT resolution in this cohort; hypothesis-generating and requires randomized trials before practice change.
Background: Data comparing different doses of non-vitamin K antagonist oral anticoagulants (NOACs) regarding resolution of left atrial appendage thrombus (LAAT) in patients with nonvalvular atrial fibrillation (AF) are scarce. This study aimed to investigate the safety and efficacy of standard-dose versus low-dose NOACs in patients with nonvalvular AF and LAAT. Methods: Patients with nonvalvular AF who underwent transesophageal echocardiography (TEE) before interventional procedures for the detection of LAAT and treated with NOACs from October 2014 to September 2020 in Ningbo First Hospital were retrospectively screened. The study population was divided into two groups according to the doses of NOACs: standard-dose group (dabigatran 150 mg, twice daily; rivaroxaban 20 mg, once daily) and low-dose group (aged ≥75 years, body weight <50 kg, or creatinine clearance <50 mL/min; dabigatran 110 mg, twice daily; rivaroxaban 15 mg, once daily). Repeated TEE was performed 1, 2, and 3 months later. The rate of LAAT completely resolved and incidence of thromboembolic and major bleeding events were compared between the two groups. Results: A total of 24 patients were included, 14 patients in the standard-dose group and 10 in the low-dose group. After 3 months, LAAT was completely resolved in 12 out of 14 (85.7%) and 8 out of 10 (80%) patients treated with standard- and low-dose NOACs, respectively. The rate of LAAT completely resolved was comparable between groups. No thromboembolic or major bleeding events occurred during the follow-up. Conclusion: Low-dose NOACs are a safe and effective option for the treatment of LAAT in some special subset patients. However, the results warrant validation in a prospective study.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2021) conducted a cohort in Nonvalvular atrial fibrillation and left atrial appendage thrombus (n=24). Standard-dose NOACs vs. Low-dose NOACs was evaluated on Rate of LAAT completely resolved. Standard-dose and low-dose NOACs resulted in comparable rates of complete left atrial appendage thrombus resolution at 3 months with no thromboembolic or major bleeding events.
Synapse has enriched 10 related papers. Consider them for comparative context: